Endo Pharmaceuticals has released data from the second Phase III study of Frova® (frovatriptan succinate) for the short-term (six days per month) prevention of menstrual Migraine (MM). This study corroborates the positive findings in a prior efficacy study published in Neurology in July 2004. Now, with two successful Phase III trials, Endo expects to file a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) in the coming weeks to seek approval for the additional indication of Frova® for the prevention of menstrual Migraine. If the application approved, Frova® will be the only triptan in the U.S. actually FDA-approved for the prevention of MM. Feature article.